Open AccessMechanisms of resistance to anti-Pd-1 therapy in metastatic cutaneous melanoma
Author(s) -
Ya. А. Zhulikov,
Igor Samoylenko,
Лев В. Демидов
Publication year - 2018
Publication title -
rossijskij bioterapevtičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 1726-9792
pISSN - 1726-9784
DOI - 10.17650/1726-9784-2018-17-1-34-46
Subject(s) - melanoma , metastatic melanoma , medicine , immunotherapy , blockade , tumor microenvironment , immune system , acquired resistance , cancer research , oncology , dermatology , immunology , cancer , receptor
The appearance of modulators immune synapse in clinical practice has become a revolution in metastatic skin melanoma treatment. However, blockade PD-1 allows to achieve objective response in only 30–40 % of patients. Recently, many mechanisms of primary resistance of melanoma to immunotherapy studied, they related both to the characteristics of the tumor and the tumor microenvironment. The response to anti-PD-1 therapy usually is durable, but acquired resistance emerges in 25 % of patients, who had an objective response to this treatment. This review will describe the main mechanisms of resistance to anti-PD-1 therapy in metastatic skin melanoma and possible ways of their overcoming.